Eleven Bio Inc (EBIO) 1.87 $EBIO
Eleven Biotherapeutics Reports First Quarter 2016 Financial Results
BusinessWire - Thu May 05, 6:30AM CDT
Eleven Biotherapeutics, Inc. (NASDAQ: EBIO), a biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today reported financial results for the first quarter ended March 31, 2016 and provided a review of recent business highlights.
EBIO: 1.87 (+0.19)
Four Top Stocks to Watch on Wednesday May 4th 2016
ACCESSWIRE - Wed May 04, 11:03AM CDT
MIAMI, FL / ACCESSWIRE / May 4, 2016 / Tech Stock Insider is issuing a report on four stocks to watch. EBIO, LCLP, XGTI, and MJNA have been added to our watch list today. Continue reading to find out why. - To get daily alerts on top stocks, subscribe to our newsletter at TechStockInsider.com.
EBIO: 1.87 (+0.19), XGTI: 0.15 (-0.02)
Genetic Stratification of Drug Response in IL-1 Implicated Eye Diseases
GlobeNewswire - Wed May 04, 7:00AM CDT
Interleukin Genetics, Inc. (OTCQB:ILIU), a life sciences company focused on developing and marketing proprietary genetic tests for chronic diseases and health-related conditions, announced today that Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), a biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, presented new data from post hoc analyses on the influence of Interleukin's IL-1 genetic patterns on response to isunakinra (EBI-005) in severe allergic conjunctivitis and severe dry eye study subjects. The data were presented at the Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) in Seattle, Washington.
EBIO: 1.87 (+0.19)
Eleven Biotherapeutics to Present Data at the ARVO 2016 Annual Meeting
BusinessWire - Fri Apr 29, 7:32AM CDT
Eleven Biotherapeutics, Inc. (NASDAQ: EBIO), a biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today announced that one oral presentation and three posters have been selected for presentation at the Association for Research in Vision and Ophthalmology (ARVO) 2016 Annual Meeting taking place May 1-5, 2016, in Seattle, WA. The presentations include preclinical data for EBI-031, which is in development for diabetic macular edema and Phase 3 clinical data on isunakinra (EBI-005). Presentation abstracts can be found on the ARVO website at https://www.arvo.org/AM/Program/.
EBIO: 1.87 (+0.19)
Why Patents are the Lifeblood of Biotech Companies
ACCESSWIRE - Mon Apr 25, 8:36AM CDT
Protection of Intellectual Property Is At the Core of the Business for Biotechnology Firms
RPTP: 5.40 (-0.09), EBIO: 1.87 (+0.19), PTCT: 7.24 (-0.30), PETX: 6.70 (-0.40), ARRY: 3.51 (-0.01)
Trending Stocks To Have On Your Watch-list Friday (4/22/16)
ACCESSWIRE - Fri Apr 22, 11:21AM CDT
MIAMI, FL / ACCESSWIRE / April 22, 2016 / Top Nasdaq Stocks is issuing a report on four stocks to watch. COOL, NEOT, EBIO, and ARTX have been added to our watch list today. Continue reading to find out why. - To get daily alerts on top stocks on the Nasdaq/NYSE subscribe to our newsletter at TopNasdaqStocks.com.
COOL: 0.88 (unch), EBIO: 1.87 (+0.19), ARTX: 2.82 (-0.06), NEOT: 1.10 (+0.01), MJCO: 5.18 (-0.22)
4 Trending Small Cap Stocks Making Big Moves Today
ACCESSWIRE - Fri Apr 22, 9:12AM CDT
NEW YORK, NY / ACCESSWIRE / April 22, 2016 / The OTC Expert is issuing a report on four stocks that are trading with heavier than usual volume. EBIO, EXXI, SUNE and ATRS are on high volume watch. Continue reading to find out why these stocks are getting so much interest today. - If you want reports on the day's hottest stocks (NYSE/Nasdaq/OTC) subscribe to our newsletter at otc-expert.com.
EXXI: 0.13 (-0.01), EBIO: 1.87 (+0.19), SUNE: 0.34 (unch), ATRS: 1.05 (-0.04)
Penny Stocks to Watch on Thursday April 21
ACCESSWIRE - Thu Apr 21, 12:08PM CDT
MIAMI, FL / ACCESSWIRE / April 21, 2016 / Daily Stock Reporter is issuing a report on four stocks to watch. CBYL, EBIO, RJETQ, and AGHI have been added to our watch list today. Continue reading to find out why. - To get daily alerts on top stocks on the OTC, NASDAQ and NYSE subscribe to our newsletter at DailyStockReporter.com.
EBIO: 1.87 (+0.19), CBYL: 1.13 (-0.11)
Top Stocks on 4/20: Investors Are Considering These on Wednesday April 20th
ACCESSWIRE - Wed Apr 20, 11:57AM CDT
MIAMI, FL / ACCESSWIRE / April 20, 2016 / Top Nasdaq Stocks is issuing a report on four stocks to watch. EBIO, ASM, OCLS, and PBMD have been added to our watch list today. Continue reading to find out why. - To get daily alerts on top stocks on the Nasdaq/NYSE subscribe to our newsletter at TopNasdaqStocks.com.
PBMD: 1.03 (-0.02), EBIO: 1.87 (+0.19), OCLS: 0.96 (unch)
Top Penny Stocks: Four Small Cap Stocks You Should Be Watching On April 15th
ACCESSWIRE - Fri Apr 15, 11:09AM CDT
MIAMI, FL / ACCESSWIRE / April 15, 2016 / Daily Stock Reporter is issuing a report on four stocks to watch. EBIO, EXXI, TLOG, and RMHB have been added to our watch list today. Continue reading to find out why. - To get daily alerts on top stocks on the OTC, Nasdaq and NYSE subscribe to our newsletter at DailyStockReporter.com.
EXXI: 0.13 (-0.01), EBIO: 1.87 (+0.19), TLOG: 0.29 (-0.02)
4 Stocks That Are Bouncing Off 52 Week Lows For Big Gains This Morning
ACCESSWIRE - Fri Apr 15, 9:16AM CDT
NEW YORK, NY / ACCESSWIRE / April 15, 2016 / The Stock Expert is issuing a report on four stocks that are trading with heavier than usual volume. GBSN, EBIO, ORPN and EXXI are on high volume alert. Continue reading to find out why GBSN could be the most talked about stock today. - To get daily alerts on the hottest stocks on the Nasdaq/NYSE subscribe to our newsletter at TheStockExpert.com.
EXXI: 0.13 (-0.01), GBSN: 1.74 (-0.09), GBSNU: 16.22 (-0.28), EBIO: 1.87 (+0.19), ORPN: 1.93 (-0.05)
Eleven Biotherapeutics Reports Fourth Quarter and Full Year 2015 Financial Results and Provides Strategic Update
BusinessWire - Thu Mar 24, 6:30AM CDT
Eleven Biotherapeutics, Inc. (NASDAQ: EBIO), a preclinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today reported financial results for the fourth quarter and full year ended December 31, 2015 and provided a strategic update and review of recent business highlights.
EBIO: 1.87 (+0.19)
Put These on Your Stocks to Watch List for Tuesday 3/15/2016, If You Choose
ACCESSWIRE - Tue Mar 15, 10:14AM CDT
CORAL GABLES, FL / ACCESSWIRE / March 15, 2016 / Daily Stock Reporter is issuing a report on four stocks to watch. NETE, EBIO, CBDS, and CPXX have been added to our watchlist today. Continue reading to find out why. - To get daily alerts on top stocks on the OTCQB, OTCQX, Nasdaq, NYSE, and OTCBB, subscribe to our newsletter at DailyStockReporter.com.
CPXX: 30.24 (+0.08), NETE: 2.29 (-0.05), EBIO: 1.87 (+0.19)
Biotech Stock Roundup: Sarepta Plunges on Briefing Documents, Acorda to Buy Biotie
Arpita Dutt - Zacks Investment Research - Wed Jan 20, 2:50PM CST
Yet another acquisition agreement was announced this week with Acorda (ACOR) announcing its intention to but Biotie. Meanwhile, DMD treatments were this week's highlights.
BIIB: 246.13 (-4.33), VRTX: 91.49 (-1.00), BMRN: 81.10 (-1.84), EBIO: 1.87 (+0.19), SRPT: 19.95 (-1.04), AMGN: 154.78 (-2.00), ACOR: 27.07 (-0.45)
Eleven Biotherapeutics' Eye Drug Fails in Phase III Study
Zacks Equity Research - Zacks Investment Research - Tue Jan 19, 3:30PM CST
Eleven Biotherapeutics (EBIO) lead eye candidate isunakinra (EBI-005) failed to hit the primary endpoint in a phase III study.
EBIO: 1.87 (+0.19), BXLT: 46.02 (-0.18), ACOR: 27.07 (-0.45), ANIK: 49.16 (+0.24)
Eleven Biotherapeutics Reports Phase 3 Data on Isunakinra (EBI-005) in Allergic Conjunctivitis
BusinessWire - Fri Jan 15, 3:01PM CST
---Company Plans to Advance Development of EBI-031 for Diabetic Macular Edema and Uveitis with an IND Submission Planned for the First Half of 2016-
EBIO: 1.87 (+0.19)
Eleven Biotherapeutics Reports Third Quarter 2015 Financial Results
BusinessWire - Wed Nov 04, 6:30AM CST
Eleven Biotherapeutics, Inc. (NASDAQ: EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today reported financial results for the third quarter ended September 30, 2015, and recent business highlights.
EBIO: 1.87 (+0.19)
Eleven Biotherapeutics to Report Third Quarter 2015 Financial Results on November 4, 2015
BusinessWire - Tue Oct 27, 7:00AM CDT
Eleven Biotherapeutics, Inc. (NASDAQ: EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today announced it will report third quarter 2015 financial results on Wednesday, November 4, 2015. Eleven's management team will host a conference call and audio webcast at 8:30 a.m. ET on Wednesday, November 4, 2015 to discuss the financial results and recent business developments.
EBIO: 1.87 (+0.19)
Eleven Biotherapeutics Completes Enrollment in Pivotal Phase 3 Study of Isunakinra (EBI-005) in Patients with Allergic Conjunctivitis
BusinessWire - Thu Oct 15, 7:00AM CDT
Eleven Biotherapeutics, Inc. (NASDAQ: EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today announced the completion of patient enrollment in its first pivotal, Phase 3 clinical study of isunakinra (EBI-005) in patients with moderate to severe allergic conjunctivitis. Isunakinra, a topical, novel interleukin-1 (IL-1) receptor blocker, is Eleven's lead drug candidate in development for the treatment of moderate to severe allergic conjunctivitis.
EBIO: 1.87 (+0.19)
Eleven Biotherapeutics Announces Promotions of Gary Sternberg, MD, MBA to Chief Business Officer and John McCabe, CPA to Senior Vice President, Finance
BusinessWire - Tue Sep 01, 7:00AM CDT
Eleven Biotherapeutics, Inc. (Nasdaq: EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, announced the promotions of Gary Sternberg, MD, MBA, to Chief Business Officer and John McCabe, CPA, to Senior Vice President, Finance. Mr. McCabe is also Eleven's Principal Financial and Accounting Officer.
EBIO: 1.87 (+0.19)
Eleven Biotherapeutics Reports First Quarter 2016 Financial Results
BusinessWire - Thu May 05, 6:30AM CDT
Eleven Biotherapeutics, Inc. (NASDAQ: EBIO), a biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today reported financial results for the first quarter ended March 31, 2016 and provided a review of recent business highlights.
EBIO: 1.87 (+0.19)
Four Top Stocks to Watch on Wednesday May 4th 2016
ACCESSWIRE - Wed May 04, 11:03AM CDT
MIAMI, FL / ACCESSWIRE / May 4, 2016 / Tech Stock Insider is issuing a report on four stocks to watch. EBIO, LCLP, XGTI, and MJNA have been added to our watch list today. Continue reading to find out why. - To get daily alerts on top stocks, subscribe to our newsletter at TechStockInsider.com.
EBIO: 1.87 (+0.19), XGTI: 0.15 (-0.02)
Genetic Stratification of Drug Response in IL-1 Implicated Eye Diseases
GlobeNewswire - Wed May 04, 7:00AM CDT
Interleukin Genetics, Inc. (OTCQB:ILIU), a life sciences company focused on developing and marketing proprietary genetic tests for chronic diseases and health-related conditions, announced today that Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), a biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, presented new data from post hoc analyses on the influence of Interleukin's IL-1 genetic patterns on response to isunakinra (EBI-005) in severe allergic conjunctivitis and severe dry eye study subjects. The data were presented at the Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) in Seattle, Washington.
EBIO: 1.87 (+0.19)
Eleven Biotherapeutics to Present Data at the ARVO 2016 Annual Meeting
BusinessWire - Fri Apr 29, 7:32AM CDT
Eleven Biotherapeutics, Inc. (NASDAQ: EBIO), a biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today announced that one oral presentation and three posters have been selected for presentation at the Association for Research in Vision and Ophthalmology (ARVO) 2016 Annual Meeting taking place May 1-5, 2016, in Seattle, WA. The presentations include preclinical data for EBI-031, which is in development for diabetic macular edema and Phase 3 clinical data on isunakinra (EBI-005). Presentation abstracts can be found on the ARVO website at https://www.arvo.org/AM/Program/.
EBIO: 1.87 (+0.19)
Why Patents are the Lifeblood of Biotech Companies
ACCESSWIRE - Mon Apr 25, 8:36AM CDT
Protection of Intellectual Property Is At the Core of the Business for Biotechnology Firms
RPTP: 5.40 (-0.09), EBIO: 1.87 (+0.19), PTCT: 7.24 (-0.30), PETX: 6.70 (-0.40), ARRY: 3.51 (-0.01)
Trending Stocks To Have On Your Watch-list Friday (4/22/16)
ACCESSWIRE - Fri Apr 22, 11:21AM CDT
MIAMI, FL / ACCESSWIRE / April 22, 2016 / Top Nasdaq Stocks is issuing a report on four stocks to watch. COOL, NEOT, EBIO, and ARTX have been added to our watch list today. Continue reading to find out why. - To get daily alerts on top stocks on the Nasdaq/NYSE subscribe to our newsletter at TopNasdaqStocks.com.
COOL: 0.88 (unch), EBIO: 1.87 (+0.19), ARTX: 2.82 (-0.06), NEOT: 1.10 (+0.01), MJCO: 5.18 (-0.22)
4 Trending Small Cap Stocks Making Big Moves Today
ACCESSWIRE - Fri Apr 22, 9:12AM CDT
NEW YORK, NY / ACCESSWIRE / April 22, 2016 / The OTC Expert is issuing a report on four stocks that are trading with heavier than usual volume. EBIO, EXXI, SUNE and ATRS are on high volume watch. Continue reading to find out why these stocks are getting so much interest today. - If you want reports on the day's hottest stocks (NYSE/Nasdaq/OTC) subscribe to our newsletter at otc-expert.com.
EXXI: 0.13 (-0.01), EBIO: 1.87 (+0.19), SUNE: 0.34 (unch), ATRS: 1.05 (-0.04)
Penny Stocks to Watch on Thursday April 21
ACCESSWIRE - Thu Apr 21, 12:08PM CDT
MIAMI, FL / ACCESSWIRE / April 21, 2016 / Daily Stock Reporter is issuing a report on four stocks to watch. CBYL, EBIO, RJETQ, and AGHI have been added to our watch list today. Continue reading to find out why. - To get daily alerts on top stocks on the OTC, NASDAQ and NYSE subscribe to our newsletter at DailyStockReporter.com.
EBIO: 1.87 (+0.19), CBYL: 1.13 (-0.11)
Top Stocks on 4/20: Investors Are Considering These on Wednesday April 20th
ACCESSWIRE - Wed Apr 20, 11:57AM CDT
MIAMI, FL / ACCESSWIRE / April 20, 2016 / Top Nasdaq Stocks is issuing a report on four stocks to watch. EBIO, ASM, OCLS, and PBMD have been added to our watch list today. Continue reading to find out why. - To get daily alerts on top stocks on the Nasdaq/NYSE subscribe to our newsletter at TopNasdaqStocks.com.
PBMD: 1.03 (-0.02), EBIO: 1.87 (+0.19), OCLS: 0.96 (unch)
Top Penny Stocks: Four Small Cap Stocks You Should Be Watching On April 15th
ACCESSWIRE - Fri Apr 15, 11:09AM CDT
MIAMI, FL / ACCESSWIRE / April 15, 2016 / Daily Stock Reporter is issuing a report on four stocks to watch. EBIO, EXXI, TLOG, and RMHB have been added to our watch list today. Continue reading to find out why. - To get daily alerts on top stocks on the OTC, Nasdaq and NYSE subscribe to our newsletter at DailyStockReporter.com.
EXXI: 0.13 (-0.01), EBIO: 1.87 (+0.19), TLOG: 0.29 (-0.02)
4 Stocks That Are Bouncing Off 52 Week Lows For Big Gains This Morning
ACCESSWIRE - Fri Apr 15, 9:16AM CDT
NEW YORK, NY / ACCESSWIRE / April 15, 2016 / The Stock Expert is issuing a report on four stocks that are trading with heavier than usual volume. GBSN, EBIO, ORPN and EXXI are on high volume alert. Continue reading to find out why GBSN could be the most talked about stock today. - To get daily alerts on the hottest stocks on the Nasdaq/NYSE subscribe to our newsletter at TheStockExpert.com.
EXXI: 0.13 (-0.01), GBSN: 1.74 (-0.09), GBSNU: 16.22 (-0.28), EBIO: 1.87 (+0.19), ORPN: 1.93 (-0.05)
Eleven Biotherapeutics Reports Fourth Quarter and Full Year 2015 Financial Results and Provides Strategic Update
BusinessWire - Thu Mar 24, 6:30AM CDT
Eleven Biotherapeutics, Inc. (NASDAQ: EBIO), a preclinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today reported financial results for the fourth quarter and full year ended December 31, 2015 and provided a strategic update and review of recent business highlights.
EBIO: 1.87 (+0.19)
Put These on Your Stocks to Watch List for Tuesday 3/15/2016, If You Choose
ACCESSWIRE - Tue Mar 15, 10:14AM CDT
CORAL GABLES, FL / ACCESSWIRE / March 15, 2016 / Daily Stock Reporter is issuing a report on four stocks to watch. NETE, EBIO, CBDS, and CPXX have been added to our watchlist today. Continue reading to find out why. - To get daily alerts on top stocks on the OTCQB, OTCQX, Nasdaq, NYSE, and OTCBB, subscribe to our newsletter at DailyStockReporter.com.
CPXX: 30.24 (+0.08), NETE: 2.29 (-0.05), EBIO: 1.87 (+0.19)
Biotech Stock Roundup: Sarepta Plunges on Briefing Documents, Acorda to Buy Biotie
Arpita Dutt - Zacks Investment Research - Wed Jan 20, 2:50PM CST
Yet another acquisition agreement was announced this week with Acorda (ACOR) announcing its intention to but Biotie. Meanwhile, DMD treatments were this week's highlights.
BIIB: 246.13 (-4.33), VRTX: 91.49 (-1.00), BMRN: 81.10 (-1.84), EBIO: 1.87 (+0.19), SRPT: 19.95 (-1.04), AMGN: 154.78 (-2.00), ACOR: 27.07 (-0.45)
Eleven Biotherapeutics' Eye Drug Fails in Phase III Study
Zacks Equity Research - Zacks Investment Research - Tue Jan 19, 3:30PM CST
Eleven Biotherapeutics (EBIO) lead eye candidate isunakinra (EBI-005) failed to hit the primary endpoint in a phase III study.
EBIO: 1.87 (+0.19), BXLT: 46.02 (-0.18), ACOR: 27.07 (-0.45), ANIK: 49.16 (+0.24)
Eleven Biotherapeutics Reports Phase 3 Data on Isunakinra (EBI-005) in Allergic Conjunctivitis
BusinessWire - Fri Jan 15, 3:01PM CST
---Company Plans to Advance Development of EBI-031 for Diabetic Macular Edema and Uveitis with an IND Submission Planned for the First Half of 2016-
EBIO: 1.87 (+0.19)
Eleven Biotherapeutics Reports Third Quarter 2015 Financial Results
BusinessWire - Wed Nov 04, 6:30AM CST
Eleven Biotherapeutics, Inc. (NASDAQ: EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today reported financial results for the third quarter ended September 30, 2015, and recent business highlights.
EBIO: 1.87 (+0.19)
Eleven Biotherapeutics to Report Third Quarter 2015 Financial Results on November 4, 2015
BusinessWire - Tue Oct 27, 7:00AM CDT
Eleven Biotherapeutics, Inc. (NASDAQ: EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today announced it will report third quarter 2015 financial results on Wednesday, November 4, 2015. Eleven's management team will host a conference call and audio webcast at 8:30 a.m. ET on Wednesday, November 4, 2015 to discuss the financial results and recent business developments.
EBIO: 1.87 (+0.19)
Eleven Biotherapeutics Completes Enrollment in Pivotal Phase 3 Study of Isunakinra (EBI-005) in Patients with Allergic Conjunctivitis
BusinessWire - Thu Oct 15, 7:00AM CDT
Eleven Biotherapeutics, Inc. (NASDAQ: EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today announced the completion of patient enrollment in its first pivotal, Phase 3 clinical study of isunakinra (EBI-005) in patients with moderate to severe allergic conjunctivitis. Isunakinra, a topical, novel interleukin-1 (IL-1) receptor blocker, is Eleven's lead drug candidate in development for the treatment of moderate to severe allergic conjunctivitis.
EBIO: 1.87 (+0.19)
Eleven Biotherapeutics Announces Promotions of Gary Sternberg, MD, MBA to Chief Business Officer and John McCabe, CPA to Senior Vice President, Finance
BusinessWire - Tue Sep 01, 7:00AM CDT
Eleven Biotherapeutics, Inc. (Nasdaq: EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, announced the promotions of Gary Sternberg, MD, MBA, to Chief Business Officer and John McCabe, CPA, to Senior Vice President, Finance. Mr. McCabe is also Eleven's Principal Financial and Accounting Officer.
EBIO: 1.87 (+0.19)
